Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas

Area of Science:

• Oncology
• Pathology
• Biochemistry

Background:

• Distinguishing malignant from benign mesothelial lesions is crucial for patient management.
• Telomerase is a key enzyme in cancer cell immortalization.
• Previous studies suggest telomerase activity may differ between malignant and benign mesothelial tissues.

Purpose of the Study:

• To assess the diagnostic utility of telomerase activity detection for differentiating malignant mesotheliomas from benign mesothelial lesions.
• To evaluate immunohistochemical and in situ hybridization methods for detecting telomerase in mesothelial tissues.
• To correlate biochemical measurements of telomerase activity with histopathological findings.

Main Methods:

• Immunohistochemistry (n=68) and in situ hybridization (n=46) were performed on malignant mesotheliomas and benign mesothelial lesions.
• Biochemical assays for telomerase activity were conducted on malignant mesotheliomas (n=9).
• Standard formalin-fixed, paraffin-embedded tissues were utilized.

Main Results:

• Telomerase activity was detected in almost all malignant mesotheliomas but rarely in benign lesions.
• Immunohistochemical staining showed high sensitivity for malignant mesotheliomas.
• In situ hybridization confirmed telomerase mRNA in malignant cells, while biochemical assays revealed strong activity.

Conclusions:

• Telomerase activity, particularly when assessed via immunohistochemistry, is a valuable biomarker for diagnosing malignant mesotheliomas.
• The findings support the use of telomerase detection in routine histopathological evaluation of mesothelial tumors.
• Immunohistochemical staining for telomerase can be reliably performed on routinely processed tissue sections.